CN111094341A - 在可变域和恒定域之间的肘区中具有功能域的抗体 - Google Patents

在可变域和恒定域之间的肘区中具有功能域的抗体 Download PDF

Info

Publication number
CN111094341A
CN111094341A CN201880048796.4A CN201880048796A CN111094341A CN 111094341 A CN111094341 A CN 111094341A CN 201880048796 A CN201880048796 A CN 201880048796A CN 111094341 A CN111094341 A CN 111094341A
Authority
CN
China
Prior art keywords
antibody
domain
antigen
polypeptide chain
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880048796.4A
Other languages
English (en)
Chinese (zh)
Inventor
安东尼奥·兰扎伟基亚
卢卡·皮科利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute for Research in Biomedicine IRB
Original Assignee
Institute for Research in Biomedicine IRB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute for Research in Biomedicine IRB filed Critical Institute for Research in Biomedicine IRB
Publication of CN111094341A publication Critical patent/CN111094341A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880048796.4A 2017-07-31 2018-07-30 在可变域和恒定域之间的肘区中具有功能域的抗体 Pending CN111094341A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EPPCT/EP2017/069357 2017-07-31
PCT/EP2017/069357 WO2019024979A1 (en) 2017-07-31 2017-07-31 FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION
PCT/EP2018/070640 WO2019025391A1 (en) 2017-07-31 2018-07-30 ANTIBODIES HAVING FUNCTIONAL DOMAINS IN THE ELBOW REGION BETWEEN A VARIABLE DOMAIN AND A CONSTANT DOMAIN

Publications (1)

Publication Number Publication Date
CN111094341A true CN111094341A (zh) 2020-05-01

Family

ID=59626578

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880048796.4A Pending CN111094341A (zh) 2017-07-31 2018-07-30 在可变域和恒定域之间的肘区中具有功能域的抗体

Country Status (13)

Country Link
US (1) US12331108B2 (enExample)
EP (1) EP3661962A1 (enExample)
JP (2) JP7297734B2 (enExample)
KR (1) KR20200032738A (enExample)
CN (1) CN111094341A (enExample)
AU (1) AU2018311032B2 (enExample)
BR (1) BR112019028180A2 (enExample)
CA (1) CA3069265A1 (enExample)
EA (1) EA202090364A1 (enExample)
IL (1) IL272303A (enExample)
MX (1) MX2020001080A (enExample)
SG (1) SG11201911658QA (enExample)
WO (2) WO2019024979A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112877394A (zh) * 2021-01-27 2021-06-01 南京大学 B7-h4+单核细胞型mdsc在制备ins激素治疗疗效预测试剂中的应用
CN114934065A (zh) * 2021-11-25 2022-08-23 浙江理工大学绍兴生物医药研究院有限公司 携带免疫检查点分子tim-3抗体基因的溶瘤腺病毒构建方法和应用

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118994394A (zh) 2017-06-12 2024-11-22 蓝鳍生物医药公司 抗-il1rap抗体和抗体药物缀合物
BR112020018918A2 (pt) 2018-03-22 2021-01-05 Surface Oncology, Inc. Anticorpos anti-il-27 e usos dos mesmos
AU2019266042B2 (en) * 2018-05-10 2025-08-07 Mirabiologics Inc. Artificial protein containing an antibody antigen-binding region, fused with bioactive peptides
MX2020012895A (es) 2018-05-30 2021-05-27 Inst Res Biomedicine Modificacion de linfocitos b al utilizar citidina desaminasa inducida por activacion endogena.
EP3927728A2 (en) 2019-02-21 2021-12-29 Xencor, Inc. Untargeted and targeted il-10 fc-fusion proteins
EP4100434A1 (en) 2020-02-03 2022-12-14 VIR Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
TWI859420B (zh) 2020-02-26 2024-10-21 美商維爾生物科技股份有限公司 抗sars-cov-2抗體及使用其之方法
WO2021203053A1 (en) 2020-04-03 2021-10-07 Vir Biotechnology, Inc. Immunotherapy targeting a conserved region in sars coronaviruses
EP4135846A1 (en) 2020-04-14 2023-02-22 VIR Biotechnology, Inc. Antibodies against sars-cov-2 and methods of using the same
JP2023525039A (ja) 2020-05-08 2023-06-14 ヴィア・バイオテクノロジー・インコーポレイテッド Ｓａｒｓ－ｃｏｖ－２に対する抗体
WO2021247925A1 (en) 2020-06-03 2021-12-09 Vir Biotechnology, Inc. Structure-guided immunotherapy against sars-cov-2
CA3180477A1 (en) 2020-06-12 2021-12-16 Elizabeth Alexander Antibody therapies for sars-cov-2 infection
EP4217385A2 (en) 2020-09-28 2023-08-02 VIR Biotechnology, Inc. Antibodies against sars-cov-2
CN112225807B (zh) * 2020-10-30 2021-09-07 上海洛启生物医药技术有限公司 抗il5纳米抗体及其应用
JP2023551667A (ja) 2020-11-23 2023-12-12 ヴィア・バイオテクノロジー・インコーポレイテッド 抗－インフルエンザ抗体及びその組合せ
KR20230135569A (ko) 2020-11-23 2023-09-25 비르 바이오테크놀로지, 인코포레이티드 인플루엔자 a 바이러스에 대한 항체
WO2022109309A1 (en) 2020-11-23 2022-05-27 Vir Biotechnology, Inc. Broadly neutralizing antibodies against influenza neuraminidase
WO2022115486A1 (en) 2020-11-25 2022-06-02 Vir Biotechnology, Inc. Antibodies that bind to multiple betacoronaviruses
EP4263600A1 (en) 2020-12-18 2023-10-25 Century Therapeutics, Inc. Chimeric antigen receptor systems with adaptable receptor specificity
EP4271715A4 (en) * 2020-12-30 2024-11-20 Wuxi Biologics Ireland Limited MULTI-SPECIFIC ANTIGEN-BINDING PROTEINS
WO2022204202A1 (en) 2021-03-23 2022-09-29 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
WO2022236142A2 (en) * 2021-05-07 2022-11-10 Senti Biosciences, Inc. Chimeric receptors and methods of use thereof
AU2022280767A1 (en) 2021-05-24 2024-01-18 Humabs Biomed Sa Engineered polypeptides
WO2023034866A1 (en) 2021-09-01 2023-03-09 Vir Biotechnology, Inc. Antibody therapies for sars-cov-2 infection in pediatric subjects
WO2023034871A1 (en) 2021-09-01 2023-03-09 Vir Biotechnology, Inc. High concentration antibody therapies for sars-cov-2 infection
EP4444758A2 (en) 2021-12-10 2024-10-16 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
US20230416406A1 (en) 2022-03-10 2023-12-28 Omeros Corporation Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease
WO2023201256A1 (en) 2022-04-12 2023-10-19 Vir Biotechnology, Inc. High dose antibody therapies for sars-cov-2 infection
WO2023230448A1 (en) 2022-05-23 2023-11-30 Vir Biotechnology, Inc. Combination immunotherapy for influenza
JP2025522295A (ja) 2022-05-23 2025-07-15 ヒューマブス・バイオメッド・ソシエテ・アノニム インフルエンザノイラミニダーゼに対する広域中和抗体
WO2023245078A1 (en) 2022-06-15 2023-12-21 Humabs Biomed Sa Anti-parvovirus antibodies and uses thereof
WO2024006472A1 (en) 2022-06-30 2024-01-04 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
EP4562034A1 (en) 2022-07-27 2025-06-04 Humabs Biomed SA Broadly neutralizing antibodies against rsv and mpv paramyxoviruses
WO2024112818A1 (en) 2022-11-22 2024-05-30 Humabs Biomed Sa Engineered anti-sars-cov-2 antibodies and uses thereof
WO2024118998A2 (en) 2022-12-01 2024-06-06 Vir Biotechnology, Inc. Engineered anti-sars-cov-2 antibodies and methods of using the same
WO2024215762A1 (en) 2023-04-10 2024-10-17 Vir Biotechnology, Inc. Antibodies that bind to multiple sarbecoviruses
WO2025010424A1 (en) 2023-07-06 2025-01-09 Vir Biotechnology, Inc. Antibodies against staphylococcus antigens and methods of using the same
WO2025015321A1 (en) 2023-07-13 2025-01-16 Vir Biotechnology, Inc. Broadly neutralizing antibodies against rsv and mpv paramyxoviruses

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220388A1 (en) * 2000-06-30 2004-11-04 Nico Mertens Novel heterodimeric fusion proteins
CN101952312A (zh) * 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
WO2012088290A2 (en) * 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
CN104903352A (zh) * 2012-12-28 2015-09-09 艾伯维公司 多价结合蛋白组合物
WO2016207402A1 (en) * 2015-06-26 2016-12-29 Institute For Research In Biomedicine Proteins comprising a mutated lair-1 fragment and uses thereof
WO2017100372A1 (en) * 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
CN112313333A (zh) * 2018-05-10 2021-02-02 秘来生物制剂株式会社 包含抗体的抗原结合区、融合生理活性肽的人工蛋白质

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
WO2005000898A2 (en) 2003-06-27 2005-01-06 Biogen Idec Ma Inc. Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
BRPI0811857A2 (pt) 2007-05-14 2014-10-21 Biogen Idec Inc Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados.
ES2525346T3 (es) 2008-10-22 2014-12-22 Institute For Research In Biomedicine Métodos para producir anticuerpos a partir de células plasmáticas
US20140235476A1 (en) * 2012-12-28 2014-08-21 Abbvie, Inc. Multivalent binding protein compositions and methods for identifying variants of same
US9814784B2 (en) 2013-01-03 2017-11-14 Celltrion, Inc. Antibody-linker-drug conjugate, preparation method therefor, and anticancer drug composition containing same
US10526404B2 (en) * 2015-04-29 2020-01-07 Institute For Research In Biomedicine Multispecific anti GM-CSF antibodies
AU2016277887B2 (en) * 2015-06-18 2022-06-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunoglobulin single variable domain antibody against RSV prefusion F protein
EA039366B1 (ru) * 2015-06-24 2022-01-19 Джей Си Ар ФАРМАСЬЮТИКАЛЗ КО., ЛТД. Антитело к рецептору трансферрина человека, проникающее через гематоэнцефалический барьер

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220388A1 (en) * 2000-06-30 2004-11-04 Nico Mertens Novel heterodimeric fusion proteins
CN101952312A (zh) * 2007-07-31 2011-01-19 米迪缪尼有限公司 多特异性表位结合蛋白及其应用
WO2012088290A2 (en) * 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
CN104903352A (zh) * 2012-12-28 2015-09-09 艾伯维公司 多价结合蛋白组合物
WO2016207402A1 (en) * 2015-06-26 2016-12-29 Institute For Research In Biomedicine Proteins comprising a mutated lair-1 fragment and uses thereof
WO2017100372A1 (en) * 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
CN112313333A (zh) * 2018-05-10 2021-02-02 秘来生物制剂株式会社 包含抗体的抗原结合区、融合生理活性肽的人工蛋白质

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
FU-LIEN HSIEH等: "The structure of a LAIR1-containing human antibody reveals a novel mechanism of antigen recognition" *
PIEPER, K.等: "Public antibodies to malaria antigens generated by two LAIR1 insertion modalities" *
TAN, J.等: "A LAIR1 insertion generates broadly reactive antibodies against malaria variant antigens" *
张冠一: "抗CD20嵌合抗体的构建、表达和功能研究以及CD20相互作用蛋白的初步研究" *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112877394A (zh) * 2021-01-27 2021-06-01 南京大学 B7-h4+单核细胞型mdsc在制备ins激素治疗疗效预测试剂中的应用
CN114934065A (zh) * 2021-11-25 2022-08-23 浙江理工大学绍兴生物医药研究院有限公司 携带免疫检查点分子tim-3抗体基因的溶瘤腺病毒构建方法和应用

Also Published As

Publication number Publication date
SG11201911658QA (en) 2020-03-30
AU2018311032A1 (en) 2019-12-05
US12331108B2 (en) 2025-06-17
KR20200032738A (ko) 2020-03-26
JP7297734B2 (ja) 2023-06-26
US20200325220A1 (en) 2020-10-15
JP2020528758A (ja) 2020-10-01
WO2019025391A1 (en) 2019-02-07
AU2018311032B2 (en) 2025-01-23
EA202090364A1 (ru) 2020-06-26
IL272303A (en) 2020-03-31
MX2020001080A (es) 2020-08-06
WO2019025391A9 (en) 2020-02-13
JP2023123588A (ja) 2023-09-05
EP3661962A1 (en) 2020-06-10
WO2019024979A1 (en) 2019-02-07
CA3069265A1 (en) 2019-02-07
BR112019028180A2 (pt) 2020-07-07

Similar Documents

Publication Publication Date Title
CN111094341A (zh) 在可变域和恒定域之间的肘区中具有功能域的抗体
JP7499498B2 (ja) 細胞の細胞質への分子の送達のための構築物
CN105829349B (zh) 肽嵌合抗原受体t细胞开关和其用途
CN112512581A (zh) 针对cldn18.2和cd3的抗体构建体
JP2015501291A (ja) ハイブリッド定常領域
CN114026123A (zh) 靶向活性基因编辑剂及使用方法
TW201139666A (en) Novel antibody having modification site introduced therein, and antibody fragment
CN116323671A (zh) 具有增加的选择性的多靶向性双特异性抗原结合分子
AU2017293450A1 (en) Humanized antibodies transmigrating the blood-brain barrier and uses thereof
CA3181617A1 (en) Cd40 binding protein
CN117157328A (zh) Multabody构建体、组合物和方法
CA3100112A1 (en) Engineering b lymphocytes by utilizing endogenous activation-induced cytidine deaminase
US10906973B2 (en) Antibody variants transmigrating the blood-brain barrier and uses thereof
JP2022523009A (ja) 脱免疫化志賀毒素ａサブユニットエフェクターを含むｃｄ３８結合性タンパク質
JP2023550191A (ja) Ｄｒ４および／またはｄｒ５を標的とするポリペプチドならびに関連する組成物および方法
HK40029066A (en) Antibodies with functional domains in the elbow region between variable and constant domain
US20250353931A1 (en) Multi-specific reagent for targeted delivery of lipid nanoparticles
EA046243B1 (ru) Антитела с функциональными доменами в области изгиба между вариабельным и константым доменом
TW202535941A (zh) 具有特製藥物對抗體比之抗體-藥物結合物
TW202509064A (zh) 靶向干擾素α融合蛋白及使用方法
HK40041672A (en) Novel anti-cd39 antibodies
CN118440197A (zh) Pd-l1鲨鱼纳米抗体的制备及其对肿瘤的影响
CN120530142A (zh) 多特异性多肽复合物
HK40068271A (en) Targeted active gene editing agent and methods of use
HK40023815A (en) Anti-cd3 antibody folate bioconjugates and their uses

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40029066

Country of ref document: HK